Acurx pharmaceuticals, inc. announces $4.225 million registered direct offering

Staten island, n.y. , july 25, 2022 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into definitive agreements with a single healthcare-focused u.s. institutional investor and certain executives of the company for the purchase and sale of an aggregate of 1,289,980 shares of its common stock (which includes 130,769 pre-funded warrants to purchase shares of its common stock being sold to the u.s. institutional investor) at a purchase price per share of $3.25 (or $3.2499 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant) for the u.s. institutional investor and $3.80 per share for the company's executives, pursuant to a registered direct offering.
ACXP Ratings Summary
ACXP Quant Ranking